|  |  |  |
| --- | --- | --- |
|  |  | **Supplemental Table 2.** Patient diagnosis, courses received, best response |
| **PT ID#** | **Cell****Type** | **Diagnosis** |  **Dose**(mg/m2/d) | **Courses****#** | **Best Response** | **PFS**(months) | **Status**(+months) |
|  6 | T-cell | NHL angioimmunoblastic | 1810a |  6 | **PRu** | 6 |  |
|  5 | T-cell | NHL cutaneous  | 1280a |  1 | n/e |  |  |
| 10 | T-cell | NHL cutaneous /Sézary | 1280a |  25 | **CR** | 68+ | CR +68c |
| 25 | T-cell | NHL cutaneous | 1280a |  7 | SD | 6 | Alive +83d |
| 26 | T-cell | NHL cutaneous | 600-1200b |  4 | SD |  |  |
| 28 | T-cell | NHL Gamma/delta | 600-1200b |  2 | SD |  |  |
| 13 | T-cell | NHL cutaneous | 905a |  3 | PD |  |  |
| 14 | T-cell | NHL angioimmunoblastic | 905a |  4 | **CRu** | 14+ | Alive +118e |
| 16 | T-cell | NHL cutaneous | 905a |  <1 | n/e |  |  |
| 17 | T-cell | NHL cutaneous /Sézary | 905a |  6 | **PRu** | 5 |  |
| 18 | T-cell | NHL cutaneous /Sézary | 640a |  12 | SD | 8 |  |
| 19 | T-cell | NHL peripheral, NOS | 640a |  3 | PD |  |  |
| 20 | T-cell | NHL angioimmunoblastic | 640a |  2 | SD |  |  |
|  7 | B-cell | CLL/SLL | 1810 |  <1 | PD |  |  |
|  9 | B-cell | NHL marginal zone | 1280 |  <1 | PD |  |  |
| 11 | B-cell | NHL diffuse large cell | 1280 |  3 | SD |  |  |
| 12 | B-cell | Hodgkin's disease (NS) | 1280 |  1 | PD |  |  |
| 23 | B-cell | Hairy cell leukemia | 1280 |  2 | SD |  |  |
| 24 | B-cell | CLL (NOS) | 1280a |  2 | PD |  |  |
| 27 | B-cell | NHL Mantle cell | 600-1200b |  1 | PD |  |  |
| 15 | B-cell | NHL follicular lymphoma | 905 |  2 | PD |  |  |
|  4 | B-cell | CLL / SLL | 640 |  1 | PD |  |  |
|  3 | B-cell | NHL diffuse large | 320 |  2 | **PRu** |  |  |
|  2 | B-cell | CLL/ SLL  | 160 |  1 | PD |  |  |
| 29 | mixed | NHL mixed PTCL / large diffuse B-cell  | 600-1200b |  1 | PD |  |  |
|  8 |  | AML-M1 | 1810 |  <1 | PD |  |  |
|  1 |  | AML-M2  | 80 |  2 | PD |  |  |
| 22 |  | Multiple myeloma | 905 |  1 | PD |  |  |
| 21 |  | ALL pre-B (pre-transplant) | 640 |  3 | n/e |  |  |
|  |  | a patient had dose reduction during protocol therapy b modified reduced Day 1 dosing c last contact – lost to follow-upd residual disease, periodic treatment with other agentse relapsed at +113 months with phenotypic drift to Follicular Helper T-cell n/e = not evaluableCRu = complete response, unconfirmed (lacking marrow response confirmation)PRu = partial response, unconfirmed (lacking marrow response confirmation) |